Focusing our energy on saving lives
|
|
- Lynette Snow
- 5 years ago
- Views:
Transcription
1 October 2017 The Outlook for Oncology: The Shrinking, Affordable Proton Therapy Center Focusing our energy on saving lives Jonathan Farr, DSc Senior Vice President Medical Physics
2 Forward Looking Statement This presentation may contain certain projections and other forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of Advanced Oncotherapy plc ( AVO, Advanced Oncotherapy or the Company ). These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Any of the assumptions underlying these forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the forward-looking statements may not actually be achieved. Nothing contained in this presentation should be construed as a profit forecast or profit estimate. Investors or other recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. Advanced Oncotherapy undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances. Neither this presentation nor any verbal communication shall constitute an invitation or inducement to any person to subscribe for or otherwise acquire securities in Advanced Oncotherapy.
3 How do we improve the targeted dose delivery with protons? Proton beam properties compared to photon Protons are charged particles That is why they release their energy in a precisely defined penetration depth in tissue In contrast, photons emit their energy along their entire path through tissue 1
4 Comparative Doses: Proton vs. Photon Therapy Approximately 40% of body doses are spared This is why it is especially suitable for children Organ damage can be reduced Higher doses are made possible Retreatments: Patients treated previously treated with radiation therapy 2
5 Proton therapy compared with photon therapy: Craniospinal (paediatric) 3
6 Expansion of Proton Therapy Worldwide >200 MeV Operating Under construction 4
7 Equipment Size Comparison Proton vs. Photon Accelerator Gantry 5
8 Proton Therapy Accessibility Goals Smaller, lighter: accelerators, beamlines, and gantries. Efficiency equal or better than photon LINAC systems. Reduced maintenance costs. Flexible system fitting a range of geometries. Reduced install costs (shielding). Reduced decommissioning cost (up to 3x cost of the installation). Reduced operational costs (manpower, energy use). Ease of use, lower barriers to entry. 6
9 Harley Street Project 141/143 Harley Street Grade 2 listed buildings Challenge: Install and Operate a high energy Proton Therapy Center here Simon Baynham, Property Director at the Howard de Walden Estate, explains the Estate s decision to approach AVO saying; Such a facility should further enhance the tremendous work already being carried out in Harley Street, by some of the world s top oncologists and radiologists in the field of cancer. 7
10 Solution: the LIGHT System Proton Source RFQ Modulator SCDTL CCL Vacuum / Support system Treatment room Smaller emittance, pulsed energy changes efficiency, lightweight transport, less shielding Modular, no moving parts Reduced operational and maintenance costs. High flux hypofractionation 8
11 Solution: Gantry Alternative 9
12 AVO Harley Street Proton Therapy Centre Design 10
13 AVO Harley Street Progress Update Deconstruct began on site January Demolition and enabling work completed. Stage II sub-structural works (groundworks, piling and excavation) well underway. Building readiness on schedule for installation by H LIGHT system installation and commissioning First patient. 11
14 Pebble Mill Project AVO is actively working with the Calthorpe Estate to deliver a compact LIGHT system in Birmingham 12
15 Thank you for your attention
EKOS. Interventional Vascular 3 February, Imagine where we can go.
EKOS Interventional Vascular 3 February, 2015 Imagine where we can go. Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other
More informationVarithena 3 rd February 2015
Varithena 3 rd February 2015 Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other forward-looking statements with respect to
More informationCommitted to Delivering Affordable Proton Cancer Therapy. Energy Focused on Saving Lives
Committed to Delivering Affordable Proton Cancer Therapy Energy Focused on Saving Lives Forward looking statement This presentation may contain certain projections and other forward-looking statements
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference Jean-Marc BOTHY - CSO June 8, 2017 2017 IBA SA Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers;
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationJefferies 2014 Global Healthcare Conference November Because people depend on us
Jefferies 2014 Global Healthcare Conference November 2014 Because people depend on us Forward-looking statements This presentation and information communicated verbally to you may contain certain projections
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationPROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION
Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition
More informationNHS Healthcare Science. Cumbria & NE LWAB. 4 th September 2018
NHS Healthcare Science Cumbria & NE LWAB 4 th September 2018 Executive Summary The Business Proton Partners International (PPI) will build, own and operate a network of Proton Beam Therapy Cancer Centres
More informationJP MORGAN HEALTHCARE CONFERENCE DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY
JP MORGAN HEALTHCARE CONFERENCE - 2017 DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY THIS PRESENTATION IS INTENDED EXCLUSIVELY FOR INVESTORS. IT IS NOT INTENDED FOR USE IN
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationProton Treatment. Keith Brown, Ph.D., CHP. Associate Director, Radiation Safety University of Pennsylvania
Proton Treatment Keith Brown, Ph.D., CHP Associate Director, Radiation Safety University of Pennsylvania Proton Dose vs. Depth Wilson,. R.R. Radiological use of fast protons. Radiology 47:487-491, 1946.
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationSHIELDING TECHNIQUES FOR CURRENT RADIATION THERAPY MODALITIES
SHIELDING TECHNIQUES FOR CURRENT RADIATION THERAPY MODALITIES MELISSA C. MARTIN, M.S., FACR, FAAPM PRESIDENT AAPM - 2017 PRESIDENT - THERAPY PHYSICS INC., GARDENA, CA MELISSA@THERAPYPHYSICS.COM AAPM Spring
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationPlans for the Precision Cancer Medicine Institute University of Oxford
Plans for the Precision Cancer Medicine Institute University of Oxford STFC & Particle Accelerators and Beams group workshop on particle accelerators for medicine 17 th February 2015 Claire Timlin The
More informationINVESTOR MEETING ASTRO 2013
INVESTOR MEETING ASTRO 2013 Webcast will begin 7:15 a.m. EDT SEPTEMBER 24, 2013 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED. Forward-Looking Statements Except for historical information, this news
More informationUpdate on Exact Sciences Molecular CRC Screening Test. November 16 th, 2011
Update on Exact Sciences Molecular CRC Screening Test November 16 th, 2011 0 Safe Harbor Statement Certain matters contained in this presentation, other than historical information, consist of forward-looking
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationMedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy
MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking
More informationWorld leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationPROGRESS IN HADRONTHERAPY
PROGRESS IN HADRONTHERAPY Saverio Braccini TERA Foundation for Oncological Hadrontherapy IPRD06 - Siena - 01.10.06 - SB 1 Outline Introduction Radiation therapy with X rays and hadrontherapy Hadrontherapy
More informationACCELERATORS FOR HADRONTHERAPY
ACCELERATORS FOR HADRONTHERAPY Alberto Degiovanni CERN-BE IVICFA s Fridays: Medical Physics Valencia, 31.10.2014 Introduction: the icon of hadrontherapy Position of the Bragg peak depends on beam energy
More informationUse of Bubble Detectors to Characterize Neutron Dose Distribution in a Radiotherapy Treatment Room used for IMRT treatments
Use of Bubble Detectors to Characterize Neutron Dose Distribution in a Radiotherapy Treatment Room used for IMRT treatments Alana Hudson *1 1 Tom Baker Cancer Centre, Department of Medical Physics, 1331
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationUK FEL R&D Plans Jim Clarke
UK FEL R&D Plans Jim Clarke STFC Daresbury Laboratory & The Cockcroft Institute IoP PAB/STFC Workshop Towards a UK XFEL 16 th February 2016 Contents UK Context & Selected FEL projects 4GLS ALICE NLS SwissFEL
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationSCANNER & SERVICES OVERVIEW
SCANNER & SERVICES OVERVIEW Tim Mack VP BUSINESS DEVELOPMENT & GM ITERO 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationEconomic Implications of Advancements in Radiation Technology. Dramatic Growth of RT Capacity in the US
Economic Implications of Advancements in Radiation Technology Sponsored by: OTN Anthony M. Berson, M.D. Radiation Oncology, St. Vincent s Comprehensive Cancer Center Richard Emery Vice President, Aptium
More information27 September Interim results for the six months ended 30 June 2018
27 September 2018 Interim results for the six months ended 30 June 2018 Disclaimer 2 Neither this presentation nor any verbal communication shall constitute, or form part of, any offer, invitation or inducement
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationImportant information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar
More informationLivaNova Investor Day
LivaNova Investor Day TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) Paul Buckman General Manager, TMVR September 14, 2017 Safe Harbor Statement Certain statements in this presentation, other than purely
More informationSOUTHAMPTON UNIVERSITY HOSPITALS NHS TRUST CANCER CARE PHASE 2A+ BUSINESS CASE
SOUTHAMPTON UNIVERSITY HOSPITALS NHS TRUST CANCER CARE PHASE 2A+ BUSINESS CASE Proposal: Report to: Trust Board Report from: Helen Lingham, Divisional Manager, Unscheduled Care Executive Sponsor: Fiona
More informationPress release Regulated information
IBA TRADING UPDATE - THIRD QUARTER 2013 Pick up in revenues over H1 2013 due to good order book conversion Company on track to be selected for eight new proton therapy (PT) rooms in 2013 REBIT margin for
More informationMedia Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)
News Release Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) 652-0059 (908) 423-5185 Janet Skidmore (267) 305-7715 Merck Launches National Advertising Campaign for GARDASIL, Merck's
More informationHigh brightness electron beam for radiation therapy A new approach
High brightness electron beam for radiation therapy A new approach Wei Gai ( 盖炜 ) Engineering Physics Department, Tsinghua University, Beijing, China Argonne National Laboratory, Argonne, IL 60439, USA
More informationBasic Press Information
Basic Press Information Contact MedAustron EBG MedAustron GmbH Marie Curie-Strasse 5 A-2700 Wiener Neustadt Austria T +43 2622 26 100-0 e-mail: office@medaustron.at Internet: www.medaustron.at Press contact:
More informationDOSIMETRIC COMPARISION FOR RADIATION QUALITY IN HIGH ENERGY PHOTON BEAMS
DOSIMETRIC COMPARISION FOR RADIATION QUALITY IN HIGH ENERGY PHOTON BEAMS EUGENIA BADITA 1, CATALIN VANCEA 1,3, ION CALINA 1,3, DANIELA STROE 2, MIHAELA DUMITRACHE 2,3, MIRABELA DUMITRACHE 1,3 1 National
More informationTheralase Presents Dosimetry Planning at International World Congress
Theralase Presents Dosimetry Planning at International World Congress Toronto, Ontario June 13, 2017, Theralase Technologies Inc. ( Theralase or the Company ) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationSarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington
Sarcoma and Radiation Therapy Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington Objective: Helping you make informed decisions Introduction Process Radiation
More informationMarket Survey. Technical Description Irradiation Tests
EDMS No. 1959184 The R2E Project Group Code: EN-STI Market Survey Technical Description Irradiation Tests Abstract This Technical Description concerns the performance of irradiation testing of CERN samples.
More informationCavosonstat Phase 2 Trial Results. November 28 th, 2016
Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David
More informationIon Beam Therapy should we prioritise research on helium beams?
Ion Beam Therapy should we prioritise research on helium beams? Stuart Green Medical Physics University Hospital Birmingham NHS Trust Follow-up from the EUCARD2 workshop, ION Beam Therapy: Clinical, Scientific
More informationONTARIO CANCER PLAN
ONTARIO CANCER PLAN 2011-2015 I want to live... I m still young, many people in my family have lived to be 100. I want to be around to watch my grandchildren grow up. Screening saved my life, I tell everybody
More informationRadiation protection in proton therapy
Radiation protection in proton therapy Pieternel van der Tol Medical Physicist - HollandPTC pvandertol@hollandptc.nl Marjan Dwarswaard René Bolt Marc-Jan van Goethem Lars Murrer Outline Introduction Interactions
More informationPancreatic Cancer Treatment
Scan for mobile link. Pancreatic Cancer Treatment What is pancreatic cancer? Pancreatic cancer begins in the pancreas, an organ located deep in the abdomen behind the stomach. The pancreas releases hormones
More informationPXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes Sébastien Bolze 1 ; Sophie Hallakou-Bozec 1 ; Michael Roden 2, 3,4 ; Julien Roux
More informationBeam Loss and Collimation in the ESS Linac
Beam Loss and Collimation in the ESS Linac Ryoichi Miyamoto (ESS) B. Cheymol, H. Danared, M. Eshraqi, A. Ponton, J. Stovall, L. Tchelidze (ESS) I. Bustinduy (ESS-Bilbao) H. D. Thomsen, A. I. S. Holm, S.
More informationUK X-FEL National Laboratory Perspective
UK X-FEL National Laboratory Perspective Susan Smith STFC ASTeC IoP PAB/STFC Workshop Towards a UK XFEL 16 th February 2016 Content Overview STFC national labs capabilities FEL R&D Underpinning accelerator
More informationBrisa Concessão Rodoviária. 1Q 2017 Traffic Update
Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationNeovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum
Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements
More informationSUMITOMO Particle Therapy Technologies
55 th AAPM annual meeting Particle Beam Therapy Symposium SUMITOMO Particle Therapy Technologies August 3, 2013 Yukio Kumata Experience accelerators for science Current Status proton and carbon Future
More informationXanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease
XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease Dr Bill Ketelbey CEO 17TH ALZHEIMER'S AUSTRALIA BIENNIAL NATIONAL DEMENTIA CONFERENCE 19 OCTOBER 2017 Disclaimer This presentation has
More informationImportant Notices. BASIS CPD Points PN/50971/1516/g
Chilli pepper results May 2016 1 Important Notices BASIS CPD Points PN/50971/1516/g This document is produced for information only and not in connection with any specific or proposed offer (the Offer )
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationPLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationDiagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014
Diagnostics for the early detection and prevention of colon cancer Publication of DeeP-C Study Data in New England Journal of Medicine March 2014 Safe Harbor Statement Certain statements made in this presentation
More informationAmendment No. 2. Item No. 2 (Rfx/ Event number )
Amendment 2 Sub: Amendment to the Document 06.12.2018 Ref.: Notice Inviting Bid ref. HITES/PCD/NCI-AIIMS/36/18-19 dated 26.09.2018 read with its Amendment no. 1 dated 19.11.18 The following changes have
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationMedical Use of Radioisotopes
Medical Use of Radioisotopes Therapy Radioisotopes prove to be useful in the application of brachytherapy, the procedure for using temporary irradiation close to the area of disease (i.e. cancer) 10% Medical
More informationTECHNOLOGY & INNOVATION
TECHNOLOGY & INNOVATION Zelko Relic VP RESEARCH & DEVELOPMENT 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationMaintenance and Logistics Experience at Loma Linda Proton Treatment Facility
Maintenance and Logistics Experience at Loma Linda Proton Treatment Facility Baldev Patyal, Ph.D., Chief Medical Physicist Department of Radiation Medicine Outline Loma Linda Proton Treatment Facility
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationpat hways Medtech innovation briefing Published: 24 August 2018 nice.org.uk/guidance/mib157
pat hways AlignRT in breast cancer radiotherapy Medtech innovation briefing Published: 24 August 2018 nice.org.uk/guidance/mib157 Summary The technology described in this briefing is the AlignRT patient
More informationElekta - a partner and world-leading supplier
Experience Elekta Elekta - a partner and world-leading supplier of clinical solutions for image guided radiation therapy, stereotactic radiotherapy, radiosurgery and brachytherapy, as well as advanced
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationElekta Infinity. Digital accelerator for advanced treatments. Redefining treatment precision, speed and control
Elekta Infinity Digital accelerator for advanced treatments Redefining treatment precision, speed and control Do you have the confidence to increase conformance and speed without compromising target coverage?
More informationTheralase Therapeutic Laser Technology Enhances Cancer Destruction
Theralase Therapeutic Laser Technology Enhances Cancer Destruction Toronto, Ontario November 27, 2017, Theralase Technologies Inc. ( Theralase or the Company ) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech
More informationClinical oncology workforce: the case for expansion Faculty of Clinical Oncology
www.rcr.ac.uk Clinical oncology workforce: the case for expansion Faculty of Clinical Oncology www.rcr.ac.uk Contents Foreword 2 1. Background information 3 What do clinical oncologists do? 3 Why is the
More informationThe Heidelberg Ion Therapy Center. Thomas Haberer Heidelberg Ion Therapy Center Hadron Therapy Workshop, Erice 2009
The Heidelberg Ion Therapy Center Thomas Haberer Heidelberg Ion Therapy Center Hadron Therapy Workshop, Erice 2009 Goal The key element to improve the clinical outcome is local l control! entrance channel:
More informationCOURSE LISTING. Courses Listed. Training for Cloud with SAP Hybris in Service Cloud (C4C) 23 August 2018 (06:31 BST) Fortgeschrittene.
Training for Cloud with SAP Hybris in Service Cloud (C4C) Courses Listed Fortgeschrittene C4C10 - SAP Hybris Cloud for Customer Administration C4C10E - SAP Hybris Cloud for Customer Administration C4C14
More informationChanging Paradigms in Radiotherapy
Changing Paradigms in Radiotherapy Marco van Vulpen, MD, PhD Mouldroomdag-2015 Towards the elimination of invasion 1 NIH opinion on the future of oncology Twenty-five years from now,i hope that we won
More informationIntroducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST)
Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST) CED Life Science Conference February 27, 2018 Almost 40% of us will be diagnosed with cancer at some point in our lives
More informationCharacterization and implementation of Pencil Beam Scanning proton therapy techniques: from spot scanning to continuous scanning
Characterization and implementation of Pencil Beam Scanning proton therapy techniques: from spot scanning to continuous scanning Supervisors Prof. V. Patera PhD R. Van Roermund Candidate Annalisa Patriarca
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationLecture 13 Radiation Onclolgy
Lecture 13 Radiation Onclolgy Radiation Oncology: Tumors attacked with ionizing radiation Photons (gamma rays) High Energy Electrons Protons Other particles Brachytherapy: implants of beta emitters Ionizing
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationNot an Offer for Securities
Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at presentations to be made by the Company. This presentation does not constitute
More informationA Rare Opportunity in Transplant.
A Rare Opportunity in Transplant. ENV-18-104.0 1 Forward Looking Statements Certain information in this presentation may constitute forward-looking information within the meaning of applicable securities
More informationAnnouncing FDA Approval of GOCOVRI TM
Announcing FDA Approval of GOCOVRI TM August 24, 2017 2017 Adamas Pharmaceuticals, Inc. All Rights Reserved. 1 Forward-looking Statements Statements contained in this presentation regarding expected future
More informationAbout Cancer Research UK
Cancer Research UK submission to the National Assembly for Wales Health and Social Care Committee inquiry into access to medical technologies October 2013 About Cancer Research UK Every year around 300,000
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationUtrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018
Utrophin Modulation: A Universal Treatment Approach to DMD April 2018 Legal Disclaimer Statements in this presentation, other than statements of historical fact, constitute forward-looking statements within
More informationDR.NEIL FRAZER CHIEF EXECUTIVE OFFICER & MANAGING 1
DR.NEIL FRAZER CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR @Dr_Neil_Frazer 1 IMPORTANT NOTICE The purpose of the presentation is to provide an update of the business of OncoSil Medical Ltd (ASX:OSL). These
More information